bota-vec最初是由 强生 公司的杨森部门与遗传医学生物技术公司MeiraGTx合作开发的。2023年12月底,强生公司以一项价值高达4.15亿美元的交易买下了该计划的全部权利。然而近日公布的三期数据,给基因疗法又破了一盆冷水。5月2日公布的结果显示,在一项针对X连锁视网膜色素变性(XLRP)患者的3期临床试验中,该基因疗法未能改善患者的视觉引导行动能力。在LUMEOS III期试验中,研究的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.